Tacrolimus in Solution as an Option to Inflammatory Conditions of the Scalp.


Journal

Dermatology practical & conceptual
ISSN: 2160-9381
Titre abrégé: Dermatol Pract Concept
Pays: Austria
ID NLM: 101585990

Informations de publication

Date de publication:
01 Apr 2023
Historique:
accepted: 22 09 2022
medline: 17 5 2023
pubmed: 17 5 2023
entrez: 17 5 2023
Statut: aheadofprint

Résumé

Several dermatological diseases lead to inflammatory conditions of the scalp. Most of these afflictions are recalcitrant and require long term maintenance treatment. We present a case series where topical tacrolimus was used in a solution vehicle for these conditions. A total of 22 patients (aged 24-90 years) with confirmed diagnosis of lichen planus pilaris (LPP), discoid lupus (DL), frontal fibrosing alopecia (FFA), erosive pustulosis of the scalp (EPS) or folliculitis decalvans (FD) were evaluated and treated with tacrolimus solution (0.1%) applied twice daily for 1 month, then once daily for another month and alternate days for 4 months. Efficacy was evaluated by an investigator global assessment, clinical and dermoscopic evaluation at weeks 4, 8 and 24. The safety assessment included monitoring of all adverse events. The study included 13 patients with LPP, 2 with DL, 2 with FD, 2 with EPS and 3 with AFF. After 1 month, 14 patients (63.6%) had a good response and 7 (31.8%) had excellent response. After 2 months, 16 patients (72.7%) had excellent response, and this response was persistent after 6 months of treatment. Tacrolimus in solution, even if not yet commercially available, was an effective and well tolerated alternative for the maintenance treatment of inflammatory conditions of the scalp.

Identifiants

pubmed: 37196296
pii: dpc.1302a89
doi: 10.5826/dpc.1302a89
pmc: PMC10188187
doi:

Types de publication

Journal Article

Langues

eng

Références

Int J Dermatol. 2021 Jul;60(7):818-828
pubmed: 33319363
Cutis. 2012 Jul;90(1):17-23
pubmed: 22908728
Clin Cosmet Investig Dermatol. 2018 Feb 27;11:91-102
pubmed: 29520159
J Investig Dermatol Symp Proc. 2005 Dec;10(3):190-3
pubmed: 16382661
Int J Dermatol. 2012 Feb;51(2):216-20
pubmed: 22250634
Clin Exp Dermatol. 2000 May;25(3):250-4
pubmed: 10844509
Int J Dermatol. 2021 Jan;60(1):25-32
pubmed: 32516510
Expert Opin Investig Drugs. 2007 Aug;16(8):1267-76
pubmed: 17685874
J Am Acad Dermatol. 2018 Jan;78(1):203-205
pubmed: 29241787
Indian J Dermatol. 2015 May-Jun;60(3):222-9
pubmed: 26120146
Dermatol Ther. 2008 Jul-Aug;21(4):245-8
pubmed: 18715293
Actas Dermosifiliogr. 2017 May;108(4):293-304
pubmed: 28117051
Am J Clin Dermatol. 2019 Jun;20(3):379-390
pubmed: 30659454
J Am Acad Dermatol. 2019 Mar;80(3):794-801.e1
pubmed: 30092322
J Am Acad Dermatol. 2011 Jul;65(1):54-64, 64.e1-2
pubmed: 21501887
J Eur Acad Dermatol Venereol. 2019 Apr;33(4):774-780
pubmed: 30633418
Dermatol Ther. 2008 Jul-Aug;21(4):238-44
pubmed: 18715292
Am J Clin Dermatol. 2009;10(6):365-81
pubmed: 19824738
J Drugs Dermatol. 2017 Nov 1;16(11):1140-1142
pubmed: 29141063

Auteurs

Camila Scharf (C)

Dermatology Unit, University of Campania L.Vanvitelli, Naples, Italy.

Gaetano Licata (G)

Dermatology Unit, San Antonio Abate Hospital, Trapani, Italy.

Giulia Briatico (G)

Dermatology Unit, University of Campania L.Vanvitelli, Naples, Italy.

Sebastiano Pellerone (S)

Dermatology Unit, University of Campania L.Vanvitelli, Naples, Italy.

Giuseppe Argenziano (G)

Dermatology Unit, University of Campania L.Vanvitelli, Naples, Italy.

Caterina Mariarosaria Giorgio (CM)

Dermatology Unit, University of Campania L.Vanvitelli, Naples, Italy.

Classifications MeSH